ArticleApplied biochemistry and biotechnology2026
Thymosin β4 Mitigates Acute Cerebral Infarction Via Inhibition of the TLR4/NF-κB Pathway and Suppression of Neuronal Pyroptosis.
Article in Applied biochemistry and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Acute cerebral infarction (ACI), a severe neurological disorder, causes significant neuronal damage and brain injury, with cellular pyroptosis and abnormal activation of signaling pathways being key pathological contributors. This study aimed to investigate the protective effect and underlying mechanism of Thymosin β4 (Tβ4) against ACI. By establishing an oxygen-glucose deprivation/reoxygenation (OGD/R) model in HT22 mouse hippocampal neurons and a middle cerebral artery occlusion (MCAO) model in rat brains, the effects of Tβ4 on neuronal pyroptosis and the TLR4/NF-κB signaling pathway were systematically evaluated. Results demonstrated that Tβ4 significantly increased HT22 cell survival after OGD/R treatment, reduced lactate dehydrogenase (LDH) release, suppressed expression of pyroptosis-related proteins including NLRP3, ASC, cleaved caspase-1, and GSDMD-N, and decreased levels of inflammatory cytokines IL-18, IL-1β, and TNF-α. In the rat MCAO model, Tβ4 significantly reduced infarct volume, improved neurological function scores, decreased cerebral edema severity, and suppressed the expression of pyroptosis-related proteins and inflammatory cytokines in brain tissue. Mechanistically, Tβ4 inhibited the activation of the TLR4/NF-κB signaling pathway induced by OGD/R or cerebral ischemia both in vitro and in vivo, including suppression of p65 nuclear translocation as confirmed by immunofluorescence staining. Further gain- and loss-of-function experiments confirmed that Tβ4's anti-pyroptotic effects are mediated, at least partially, through inhibition of the TLR4/NF-κB pathway. In summary, Tβ4 exerts neuroprotective effects against ACI by suppressing the TLR4/NF-κB signaling pathway and mitigating neuronal pyroptosis, demonstrating potential clinical application value.
Indexed as
Identifiers
42593616What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.